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ABSTRACT
The transforming growth factor-b (TGF-b) is a family of structurally related proteins that comprises of TGF-b, activins/inhibins, and bone
morphogenic proteins (BMPs). Members of the TGF-b family control numerous cellular functions including proliferation, apoptosis,
differentiation, epithelial-mesenchymal transition (EMT), and migration. The first identified member, TGF-b is implicated in several human
diseases, such as vascular diseases, autoimmune disorders, and carcinogenesis. Activation of the TGF-b receptor by its ligands induces the
phosphorylation of serine/threonine residues and triggers phosphorylation of the intracellular effectors, SMADs. Upon activation, SMAD
proteins translocate to the nucleus and induce transcription of their target genes, regulating several cellular functions. TGF-b dysregulation
has been implicated in carcinogenesis. In early stages of cancer, TGF-b exhibits tumor suppressive effects by inhibiting cell cycle progression
and promoting apoptosis. However, in late stages TGF-b exerts tumor promoting effects, increasing tumor invasiveness, and metastasis.
Furthermore, the TGF-b signaling pathway communicates with other signaling pathways in a synergistic or antagonisticmanner and regulates
cellular functions. Elevated TGF-b activity has been associated with poor clinical outcome. Given the pivotal role of TGF-b in tumor
progression, this pathway is an attractive target for cancer therapy. Several therapeutic tools such as TGF-b antibodies, antisense
oligonucleotides, and small molecules inhibitors of TGF-b receptor-1 (TGF-bR1) have shown immense potential to inhibit TGF-b signaling.
Finally, in the interest of developing future therapies, further studies are warranted to identify novel points of convergence of TGF-bwith other
signaling pathways and oncogenic factors in the tumor microenvironment. J. Cell. Biochem. 117: 1279–1287, 2016. © 2016Wiley Periodicals, Inc.
KEY WORDS: CELL SIGNALING; PROLIFERATION; EMT; METASTASIS; INVASION
TGF-b is a sizeable superfamily of cytokines that include theTGF-bs (TGF-b1, -b2, and -b3), activins, inhibins, Anti-
Mullerian Hormone (AMH), Bone Morphogenic Protein (BMPs),
Growth Differentiation Factors (GDFs), Glial-derived Neurotrophic
Factors (GDNFs), and nodals [Massague, 2012]. The TGF-b signaling
pathway is instrumental in regulating crucial cellular activities such as
cell growth, differentiation, apoptosis,motility, invasion, extracellular
matrix production, angiogenesis, and immune response. In cancer,
TGF-b has a dual role. In the early stages of cancer development,
TGF-b operates as a tumor suppressor, whereas the opposite is true in
late stages, supporting invasion and metastasis by modulating the
immune system and tumor microenvironment. All three isoforms of
TGF-b (TGF-b1, TGF-b2, and TGF-b3) are synthesized in cells as
precursor molecules containing a propeptide region in addition to the
TGF-b homodimer. The TGF-b homodimer interacts with a Latency
Associated Peptide (LAP) forming the Small Latent Complex
(SLC). This complex remains in the cell until it binds to the Latent
TGF-b-Binding Protein (LTBP), forming a larger complex termed as
Large Latent Complex (LLC). The LLC is secreted into the extracellular
matrix in an inactive form, which prevents its binding to its receptors.
The release of the LLC from the matrix, followed by proteolysis of the
LAP releases the active TGF-b to its receptors [Hyytiainen et al., 2004].
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There are three TGF-b receptors (TGFbRI, TGFbRII, and TGFbRIII).
Both TGFbRI and TGFbRII contain serine/threonine protein kinases
in their cytoplasmic domains while TGFbRIII has no kinase activity.
Binding of TGF-b to TGFbRII, and hetero-tetramerization with
TGFbRI initiates the intracellular signaling via SMADs. TGFbRIII
functions as a coreceptor to increase the binding of ligands to
TGFbRII [Massague, 2012].
TGF-b SIGNALING PATHWAY
The active TGF-b mediates its effect by binding to TGFbRII and
modifying its conformation, then the type II receptor phosphorylates
TGFbRI on specific serine and threonine residues (Fig. 1). The
internalization of the heteromeric receptor complex materializes via
the clathrin- and lipid raft-caveolae endocytic routes. The two
discrete internalization paths determine whether the receptor
complex will induce a signaling response or receptor degradation
[Itoh and ten, 2007; Neuzillet et al., 2015; Papageorgis, 2015].
In the canonical pathway, the activated receptor complex
phosphorylates receptor-SMADs (R-SMADs), which are cytosolic
effectors responsible for activating multiple downstream signaling
pathways. The clathrin-dependent internalization of TGF-b receptor
complex initiates signaling by steering the receptor complex to early
endosomes. The SMAD anchor for receptor activation (SARA) and
cytoplasmic form of promyelocytic leukemia protein (cPML) on early
endosomes recruit R-SMADs (SMAD-1, 2, and 3) to the activated
receptor complex. Eventually R-SMADs are phosphorylated by
activated type I receptor permitting R-SMADs association with
SMAD4. The activated SMAD complex is transported to the nucleus,
where it directly or indirectly regulates gene expression by
controlling epigenetic processes, such as chromatin remodeling or
by upholding promoter DNAmethylation, which is vital in silencing
epithelial gene expression in cells that have undergone epithelial-to-
mesenchymal transition [Neuzillet et al., 2015; Papageorgis, 2015].
Trafficking of TGF-b receptor complex controls the activity and
termination of signaling events. The lipid rafts-caveolae micro-
domains are enriched with cholesterol and caveolin. The receptor
complex that is endocytosed into lipid rafts-caveolae is bound to
degrade. The activity of TGF-b signaling is regulated by the
inhibitory activity of SMAD7. Under basal conditions, SMAD7 is
localized within the nucleus of the cell. However, upon formation of
Fig. 1. TGF-b ligand binds to TGFbRII prompting the formation of a hetero-tetrameric receptor complex composed of TGFbRI and TGFbRII. The binding of ligand and
subsequent oligomerization triggers TGFbRII to phosphorylate TGFbRI on serine or threonine residues. In the canonical pathway the activated receptor complex phosphorylates
R-SMAD (SMAD2 or SMAD3) which then forms a heteromeric complex with SMAD4 and translocates to the nucleus where it interacts with various transcription factors,
coactivators, or corepressors to regulate target gene expression. In the non-canonical pathway, TGF-b can activate the MAPKs, NFkB, Ras, TRAF6, TAK1-p38/JNK, and PI3K
kinases, leading to various biological effects. Receptor complexes endocytosed into lipid rafts-caveolae are degraded by I-SMADs recruitment of Smurfs.
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TGFb-induced receptor complex, it moves to the cell membrane and
binds to a receptor complex, blocking interaction between R-SMADs
and receptor complex and hence the inhibition of downstream
TGF-b signaling. In addition, SMAD7 can antagonize the formation
of a functional SMAD-DNA complex by binding to DNA and
consequently blocking TGF-b-mediated transcriptional events. In
some instances, SMAD7 represses TGF-b signaling by interacting
with E3-ubiquitin ligases. In the nucleus, SMAD7 forms a complex
with E3-ubiquitin ligases Smurf1 or Smurf2, and upon TGF-b
activation, the complex translocates to the plasma membrane where
Smurf induces ubiquitination for proteasomal degradation of the
TGF-b receptors [Itoh and ten, 2007; Neuzillet et al., 2015;
Papageorgis, 2015].
Although the SMADs are fundamental for the TGF-b modulated
diverse cellular responses, there are numerous signaling responses
stimulated by TGF-b that occur independently of the SMAD proteins.
Mounting evidence has revealed that in the non-canonical pathway,
the activated TGF-b receptor complex conveys signals through a
number of factors such as tumor necrosis factor (TNF), receptor-
associated factor 4 (TRAF4), TRAF6, TGFb-activated kinase 1 (TAK1),
p38 mitogen-activated protein kinase (p38 MAPK), p42/p44 MAPK,
RHO, phosphoinositide 3-kinase PI3K/AKT, extracellular signal-
regulated kinase (ERK), JUN N-terminal kinase (JNK), or nuclear
factor-kB (NF-kB) to reinforce or attenuate downstream cellular
responses [Itoh and ten, 2007; Mu et al., 2012; Papageorgis, 2015].
CONTRASTING ROLES OF TGF-b
It is widely recognized that TGF-b plays central roles in
carcinogenesis. Several studies have clearly revealed dual roles of
TGF-b in this process. TGF-b is reported to suppress growth of
normal and premalignant epithelial cells. However, accumulation of
genetic and epigenetic alterations in cancer cells switches the TGF-b
function. Cancer cells produce and secrete TGF-b which promotes
their invasive and metastatic potential [Nagaraj and Datta, 2010;
Massague, 2012]. In normal epithelial cells, TGF-b acts as a tumor
suppressor and regulates cell proliferation, apoptosis, differentia-
tion, senescence, adhesion, and motility. TGF-b restrains the
proliferation of many human cell lines and tissues including
thyroid, hepatocytes, colon and mammary epithelial cells [Mas-
sague, 2012]. Studies have shown tissue specific inactivation of
TGFbRII results in spontaneous tumor formation with no pathology
in many organs implying that TGF-b elicits its antiproliferative
effects in precise settings [Nagaraj and Datta, 2010]. Loss of TGF-b
induced growth arrest can be due to either the abnormal expression
of positive regulators of cell cycle, for example the cyclins and
cyclin-dependent kinases (cdks), or the negative regulators, for
instance the cdk inhibitors. The loss of c-myc in epithelial cells and in
cancer cells coincides with a loss of c-myc promoter responsiveness
to TGF-b [Massague, 2012; Principe et al., 2014]. TGF-b inhibits
epithelial cell proliferation by causing cycle arrest at the G1 phase,
and inducing or activating cyclin-dependent kinase inhibitors
(p16INK4A, p15INK4B, p21CIP1, and/or p27Kip1), and attenuating
myc, DNA-binding protein inhibitor ID-1 (Id1) and Id2. In cancer
cells TGF-b is unable to elicit changes in myc, ID-1, and ID-2 due to
somatic mutations in components of the TGF-b signaling pathway
[Massague, 2012; Neuzillet et al., 2015]. The mechanism by which
TGF-b acts as a tumor suppressor is through inactivation of TGF-b
receptors and SMADs. The downregulation of receptors, and
increased expression of TGF-b signaling inhibitors has been
reported in human cancers [Nagaraj and Datta, 2010; Principe
et al., 2014]. It is well established that TGF-b produced by tumor cells
acts on itself in an autocrine manner to stimulate tumor suppressive
biological responses. A number of studies suggest that TGFbRI and
TGFbRII are tumor suppressor genes. Mutations in TGFbRI and
TGFbRII are linked with ovarian, cervical, gastric, head, and neck
carcinomas. Furthermore, inactivating mutations in TGFbRI and
TGFbRII have also been described in human lymphoma [Nagaraj and
Datta, 2010]. TGFbRIII is expressed in epithelial cells and considered
as a suppressor of cancer progression. However, loss of TGFbRIII
expression has been correlated with disease progression and poor
patient prognosis. Furthermore, restoration of TGFbRIII in cancer
cells demonstrated a direct role for TGFbRIII in regulating cell
migration, invasion, angiogenesis, and metastasis in vitro and
in vivo [Massague, 2012; Principe et al., 2014; Neuzillet et al., 2015].
Most types of cancers exhibit insensitivity to TGFb-mediated
growth inhibition. In colorectal, pancreatic, gastric, and prostate
tumors insensitivity to TGFb-mediated growth inhibition is
attributed to the loss of function or truncating mutations in TGFbRI,
TGFbRII, SMAD2, and SMAD4 genes. In pancreatic and colorectal
cancers, loss of 18q21 chromosome, which harbors the SMAD4 gene
is reported. Restitution of SMAD4 expression in pancreatic cancer
cell lines decreases VEGF levels resulting in suppression of tumor
growth and angiogenesis [Principe et al., 2014; Papageorgis, 2015].
In some cancers, genetic alterations or gene mutations are not
detected, suggesting existence of other methods for acquiring
resistance to TGF-b-mediated growth inhibition. In mammary and
lung epithelial cells, activation of the Ras oncogene and its
downstream target ERK leads to phosphorylation of SMAD2/3 in
the linker region, as a consequence SMADs are retained in the
cytoplasm and degraded by ubiquitin [Schwarte-Waldhoff et al.,
2000; Papageorgis, 2015].
TGF-b AND EPITHELIAL TO MESENCHYMAL TRANSITION
One of the key mechanisms by which TGF-b promotes cell migration,
invasion, and metastasis is through induction of epithelial-mesen-
chymal transition (EMT). It is a multi-step process in which cells lose
apical-basal cell polarity, and gain spindle-shaped, fibroblast-like
morphology distinctive for mesenchymal cells. The EMT process can
be categorized into three well-defined subtypes based the biological
settings andcircumstances inwhich theEMTevent is activated. Type1
EMT, also known as developmental EMT, occurs during embryogene-
sis to assist development of organs and tissues. Commencement of
type 1 EMT stimulates gastrulation and formation of ectodermal,
mesodermal, and endodermal tissues from the primitive streak. It also
instigates neural tube formation during spinal and cerebral develop-
ment. Disruption of TGF-b isoforms and their receptors has been
associated with defects in the initiation of type 1 EMT during
organogenesis and tissue morphogenesis [Principe et al., 2014;
Neuzillet et al., 2015]. Type 2 EMT is induced in response to
inflammation, particularly during wound healing and tissue regener-
ation, but ceases once inflammation is diminished [López-Novoa and
Nieto, 2009]. TGF-b plays an instrumental role inmediating the type 2
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EMT process by promoting myofibroblast activation and differentia-
tion in conjunction with extracellular matrix (ECM) remodeling, a
process that is essential for tissue repair [Taylor et al., 2010]. Type 3
EMT is most prevalent for oncogenically transformed cells that have
the capacity to metastasize. This EMT program is a requisite for the
acquisitionofmalignant phenotypes byepithelial cancer cells. In vitro
studies suggest a major role of TGF-b/SMAD signaling in the
induction of EMT in cancer cells. The adhesion molecule E-cadherin
located at cell-cell adhesion junctions is an essential molecule for the
formation andmaintenance of the epithelial phenotype. The hallmark
of EMT is loss of E-cadherin andup regulation of vimentin, slug, snail,
and fibronectin which are critical for attainment of motility and
invasive properties, and permits the cells to migrate through the
extracellular matrix and formmetastases at distant sites [Thiery et al.,
2009; Principe et al., 2014].
The entire range of signaling mediators that contribute to EMT of
carcinoma cells is far from complete. It is suggested that the genetic
and epigenetic changes experienced by cancer cells during the
process of primary tumor formation make them particularly
responsive to EMT-inducing heterotypic signals initiating in the
tumor-associated stroma. EMT-inducing signals stemming from the
tumor-associated stroma, mainly hepatocyte growth factor (HGF),
epidermal growth factor (EGF), platelet-derived growth factor
(PDGF), and TGF-b, seem to be accountable for the induction or
functional activation of a series of EMT-inducing transcription
factors, especially slug, snail, twist, zinc finger E-box binding
homeobox 1 (ZEB1), Goosecoid, and FOXC2 in cancer cells. Upon
expression and activation, the transcription factors choreograph the
EMT in conjunction with the other transcription factors. The
execution of EMT in cancer cells depends on additional signal
transducers including SMADs, ERK, MAPK, PI3K, AKT, RhoB, b-
catenin, lymphoid enhancer binding factor, Ras, c-Fos, and cell
surface (b4 integrins, a5b1 integrin, and aVb6 integrin) proteins
[Lindsey and Langhans, 2014; Barriere et al., 2015].
TGF-b has been shown to induce EMT in certain types of cancer
cells. TGF-b-induces EMT either through canonical or non-canonical
pathways. The TGFbRI and its effector SMAD proteins mediate the
epithelial tomesenchymal transition inNMuMGbreast epithelial cells
[Piek et al., 1999]. TGF-b produced by an autocrine mechanism
support and strengthen the EMT program. Evidence of collaboration
of b-catenin and LEF with SMADs in inducing an EMT has been
reported. Studies have demonstrated interaction of LEF andb-catenin
in PDGF-induced EMT. Together these studies exhibit the TGF-b/
SMAD/LEF/PDGF axis as a key player of an EMT phenotype in cancer
[Eger et al., 2000; Principe et al., 2014; Neuzillet et al., 2015].
In addition to SMADs mediated EMT process, TGF-b induces EMT
via the non-canonical pathway. In NMuMG mouse mammary
epithelial cells, integrin b1 mediates the activation of latent TGF-b
by aVb6 integrin, which in association with p38 MAPK and RhoA,
mediates an autocrine TGF-b-induced EMT. Blocking RhoA or its
downstream target p160ROCK, by the expression of dominant-negative
mutants, inhibits TGF-b–mediated EMT. Fibulin-5 (FBLN5), a
TGF-beta target gene is shown not only to stimulate matrix
metalloproteinase expression and activity, but also initiates EMT by
elevating twist expression and reducing E-cadherin expression in
breast cancer. In H-Ras transformed EpH4 mammary epithelial cells
(EpRas), TGF-b induces EMT by decreasing the expression of
glutaredoxin 1 (Grx1), MEK/MAP kinase and phosphatidylinositol-3
kinase (PI3K) signaling. Pre-treatment of H-Ras transformed
EpH4 cells with ROS scavenger N-acetylcysteine (NAC) inhibited
TGF-b1-induced EMT [Lee et al., 2010; Lindsey and Langhans, 2014].
BLOCKING TGF-b SIGNALING
TGF-b has a wide array of effects on tumorigenesis. Cancer initiation
and progression is attributed to elevated TGF-b levels. Thus blockade
of TGF-b signaling may provide therapeutic opportunities to inhibit
tumor growth and metastasis. A number of strategies such as the use
of ligand traps, small molecule inhibitors, antisense oligonucleo-
tides, and small molecule receptor kinase inhibitors are employed to
disrupt the TGF-b signaling pathway [Korpal and Kang, 2010;
Lampropoulos et al., 2012]. Ligand traps include neutralizing
antibodies developed against each TGF-b ligands and soluble decoy
receptor proteins that incorporate the ectodomains from either
TGFbRII or TGFbRIII. Ligand traps effectively block the excess TGF-b
produced by tumor cells and fibroblasts during cancer progression
that contribute to tumor aggressiveness. Studies employing a pan-
neutralizing anti-mouse TGF-b monoclonal antibody, 1D11
(Genzyme Corp., Sanofi), which binds to all three TGF-b isoforms
or recombinant Fc-fusion proteins containing the soluble ectodo-
main of either TFGbRII (TGFbRII-Fc) or TGFbRIII have shown to
decrease metastasis in breast cancer models [Connolly et al., 2012].
Another way of inhibiting TGF-b signaling is to use antisense
oligonucleotides. Targeting human TGF-b2 RNA with specific
antisense oligonucleotide demonstrated inhibition of TGF-b2
expression and reduced proliferation and migration in pancreatic
cancer in vitro and in vivo [Schwarte-Waldhoff et al., 2000].
Preclinical data suggest that small molecule inhibitors, SB-431542
or Ki26894 (GlaxoSmithKline) developed for blocking TGFbRI when
used in orthotopic xenograft model, showed decreased metastasis
and prolonged mouse survival [Ehata et al., 2007]. An alternative
strategy to block TGF-b signaling is to interfere with the SMADs.
Peptide aptamers have a target-binding domain and a scaffolding
domain which stabilizes the resulting molecular complex. A peptide
aptamer Trx-SARA binds to SMAD2 and SMAD3 and disrupts their
interactions with SMAD4. Treatment of murine mammary epithelial
cells with Trx-SARA resulted in reduction of SMAD2/3 levels and
inhibition of TGF-b-induced EMT [Zhao and Hoffmann, 2006].
Treatment of tumor cells with a combination of vaccines and
antisense TGF-b therapy showed a reduction of tumor size and
increased survival benefit [Principe et al., 2014; Neuzillet et al., 2015].
Furthermore, the results of preclinical studies have shown that TGF-b
inhibition can enhance therapeutic efficacy of cytotoxic agents
[Neuzillet et al., 2015]. The anti-TGF-b treatments deemed safe as
daily administration of a high dose of neutralizing TGF-b antibody in
adult mice showed no adverse effects on their health [Kulkarni et al.,
1993].
CROSSTALK OF TGF-b SIGNALING WITH OTHER PATHWAYS
INTERFERONS
The TGF-b pathway crosstalks with several pathways associated
with tumor progression (Fig. 2). Interferons (IFNs) are a group of
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pleiotropic cytokines and have a pivitol role in host defense and
immune surveillance. In mammals, there are two types of IFNs, type I
and type II. Type I IFN, includes IFN-a and IFN-b. Type II IFN has a
solo member IFN-g. Dual role of IFN-g has been reported in
carcinogenesis. Interaction between TGF-b and IFN-g has been
alluded by several investigators. In poorly differentiated human
gastric carcinoma cell line (GCTM-1), TGF-b enhances invasive
potential of cells whereas IFN-g inhibits TGF-b dependent invasion
by inhibiting the phosphorylation of SMAD2/3 and therefore the
translocation of SMAD complex to the nucleus. In addition to this
mechanism, IFN-g via JAK1 and STAT1 induces the expression of
SMAD7, an antagonistic SMAD which excludes the interaction of
SMAD3 with the TGF-b receptor [Kuga et al., 2003]. Crosstalk of two
pathways was further substantiated during wound healing.
Although platelets are the main source of TGF-b, fibroblasts also
produce TGF-b mRNA and protein. TGF-b has been shown to
stimulate proliferation of normal fibroblasts and healing of wounds.
Collagen plays a crucial role in healing of wounds of skin and other
tissues while TGF-b is the major growth factor involved in collagen
synthesis. Compared to normal fibroblasts, collagen synthesis is
shown to be greater in wounds and can be induced by TGF-b. IFN-g
has been to shown to negatively modulate the wound healing
process by suppressing the production and functional activity of
TGF-b1. Thus, blocking the IFN-g signal transduction pathway may
accelerate wound healing by augmenting TGF-b1 production
[Tredget et al., 2000].
TNF-a PATHWAY
Tumor necrosis factor alpha (TNF-a) is a multifunctional cytokine
implicated in apoptosis, cell survival, inflammation, and immunity.
It acts via TNF receptor 1 and TNF receptor 2. The latter is expressed
only on immune cells, while the former is expressed in every cell.
TNF receptor 1 has the death domain (DD), while it is absent in TNF
receptor 2. TNF-a is a modulator of tumor grow in vitro and in vivo.
TNF-a has been shown to increase the secretion of TGF-b in MCF-7
and ZR-75-1 breast cancer cell lines. Both cytokines were able to
induce apoptosis synergistically in Schwann, endothelial and in
SNU620 human gastric cancer cells. The TGF-b and TNF-a-induced
apoptosis is shown to be mediated by crosstalk between SMAD3 and
JNK signaling, regulating the expression and stability of Bim (a pro-
apoptotic member of the BCL-2 protein family). Furthermore,
knockdown of Bim has been shown to block both TGF-b and TNF-a-
induced apoptosis. A recent study has suggested crosstalk between
TNF-a and TGF-b during induction of EMT in A549 lung
adenocarcinoma cells. In these cells TNF-a induces phosphorylation
of SMAD2 in the linker region, and modulates SMAD regulated gene
transcription which results in EMT [Saito et al., 2013].
NOTCH PATHWAY
Notch pathway comprises of four Notch receptors (Notch1-4) and
five canonical ligands of the Delta-Serrate-Lag (DSL) type [Jag1,
Jag2, delta-like 1 (Dll1), Dll3, and Dll4]. These receptors and ligands
can make a large number of receptor-ligand combinations, with the
ability to produce multiple responses. Notch signaling is initiated by
ligand Delta–Serrate–LAG2 (or DSL) binding to transmembrane
Notch receptor, which undergoes a two-step proteolytic cleavage by
ADAM family proteases and g-secretase, releasing the Notch
Intracellular Domain (NICD). The NICD translocates to the nucleus
where it binds to the C protein binding factor 1 (CSL) and changes the
complex from a repressor to an activator of Notch target genes.
Notch pathway is activated in a number of cancers. Crosstalk
between Notch and TGF-b pathway has been well demonstrated. In
mammary epithelial cells at the onset of EMT, TGF-b induces
expression of the hairy/enhancer-of-split-related transcriptional
repressor, Hey1 and the Notch-ligand, Jagged1 (Jag1). If either Hey1,
Jagged1, Notch, or SMAD3 is inactivated, TGF-b fails to induce EMT
in mammary epithelial cells [Zavadil et al., 2004]. Notch1 abrogates
the anti-proliferative property of TGF-b by sequestering the p300
co-factor from SMADs, while silencing Notch1 expression rescues
the responsiveness to TGF-b in human cervical carcinoma cell line,
CaSki [Masuda et al., 2005].
HEDGEHOG PATHWAY
In mammals, three hedgehog (HH) ligand proteins (Sonic HH-sHH,
Indian HH-IHH, and Desert HH-DHH) are reported. The two
transmembrane protein receptors, Patched 1 and Patched 2, function
as tumor suppressors inhibiting downstream signaling proteins
Smoothened (Smo) and Gli from activating downstream signaling
components and transcription of target genes. The HH pathway is
activated upon binding of any of the three ligands to Patched
receptor, which eases Patched-mediated suppression of Smo and
triggers the translocation of the active form of Gli to the nucleus to
activate target genes expression [Amakye et al., 2013]. Activation of
the HH pathway has been found in the majority of human cancers.
Crosstalk between HH and TGF-b signaling is evident as TGF-b
induces Gli2 transcription and upregulation of Gli1 in normal
fibroblasts, keratinocytes, andMDA-MB-231 breast carcinoma cells.
In vivo studies have also shown the modulation of Gli expression in
mouse models overexpressing TGF-b1 in the epidermis. Similarly,
HH signaling has been shown to induce the expression of TGF-b
signaling proteins that are involved in SMO-dependent tumorigen-
esis affecting motility and invasiveness of gastric cancer cells.
Blocking TGF-b expression and function diminished Gli-mediated
HH signaling and reduced cell growth [Dennler et al., 2007]. During
Fig. 2. TGF-b pathway communicates with other signaling pathways and
regulates numerous key tumorigenic processes.
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the development of the cerebellum, it is demonstrated that sHH
accelerates the growth of granule cell precursors (GCPs). These cells
also express bone morphogenetic proteins (BMPs) that belong to the
transforming growth factor beta (TGF-b) family. It is reported that in
granule cell progenitors (GCPs) the BMP-2 and -4 antagonize the
proliferative function of sHH through SMAD5. In addition, BMP
downregulates sHH signaling proteins Smo and Gli1. One such
mechanism by which BMP-2 inhibits proliferation and promotes cell
differentiation of GCPs is downregulation of oncogene n-myc
[Alvarez-Rodriguez et al., 2007].
WNT PATHWAY
There are three types of Wnt signaling pathways. The canonical Wnt
pathway, the non-canonical planar cell polarity pathway, and the
non-canonical Wnt/calcium pathway. All of these pathways direct
signals from outside of a cell through cell surface receptors to the
inside of the cell. They are activated by the binding of a Wnt-protein
ligand to a frizzled family receptor, which delivers the biological
signal to the protein dishevelled inside the cell. The canonical Wnt
pathway manages to regulate gene transcription, the non-canonical
planar cell polarity pathway controls the cytoskeleton that is
accountable for the shape of the cell, and the non-canonical Wnt/
calcium pathway regulates calcium inside the cell [Blagodatski et al.,
2014; Tai et al., 2015]. TheWnt signaling pathway is pro-oncogenic,
and the TGF-b signaling pathway exhibits both inhibitory and
proliferative effects. However, both pathways participate in cancer
formation and progression. The Wnt and TGF-b pathways crosstalk
at multiple levels. The two pathways mutually regulate their ligand
production. A functional interaction between SMAD7 and b-catenin
was demonstrated in prostate cancer cells. Treatment of PC-3 cells
with TGF-b increased the levels of b-catenin and LEF1 in a SMAD7-
dependent manner. This interaction was critical for TGF-b-induced
b-catenin-regulated apoptosis. Transfection of PC-3 cells with b-
catenin siRNA protected cells from TGF-b induced apoptosis, further
demonstrating the cooperation of SMAD7 and b-catenin in
apoptosis of cells [Edlund et al., 2005]. In human mesenchymal
stem cells, a new form of crosstalk between the TGF-b and Wnt
signaling which is independent of alterations in b-catenin stability
and phosphorylation status has been reported. In these cells, the
signaling was initiated by the TGF-b receptor-mediated phosphor-
ylation of SMAD3, which disrupted the protein complex as revealed
by the diminished interactions between SMAD3 and glycogen
synthase kinase 3b (GSK-3b). Dissociation of protein complex
conceded cotranslocation of b-catenin and SMAD3 into the nucleus
[Jian et al., 2006]. In mammary gland epithelial cells, the
interdependence of Wnt and TGF-b was shown by identifying
Wnt and TGF-b target genes. Cells treated with a combination of
Wnt and TGF-b expressed Ankrd1, Ccnd1, Ctgf, Gpc1, Hs6st2, IL11,
Inhba, Mmp14, and Robo1, genes that were not expressed in single
ligand treated cells. In breast and colon cancer transgenic mouse
models, many of the genes identified in in vitro studies were found
also overexpressed in vivo. TGF-b pathway inactivation in animals
reduced the expression of some of the identified genes and impeded
tumor growth, emphasizing that TGF-b and Wnt synergistically
promote tumorigenesis [Labbe et al., 2007]. In colon cancer cells,
decreased expression of SMAD4 was associated with increased
expression of b-catenin mRNA and Wnt target genes, c-myc and
Axin2. In human embryonic kidney (HEK293T) cells, inhibition of
SMAD4 expression and BMP receptor signaling results in augmen-
tation of b-catenin expression and Wnt signaling [Freeman et al.,
2012; Peng et al., 2015].
HIPPO PATHWAY
The Hippo pathway is a key regulator of cell growth, proliferation,
apoptosis, and cell-fate decisions. The main components of this
pathway are the STE20 kinases (MST1 and MST2) and the NDR
kinases (LATS1 and LATS2), which controls the phosphorylation of
TAZ and YAP. One of the functions of TAZ/YAP pathway is to assign
active SMAD complex a cytoplasmic or nuclear localization in the
cells. Following TGF-b stimulation, TAZ binds to SMAD2 and
translocates to the nucleus to activate target genes. TAZ knockdown
in HepG2 cells inhibited nuclear accumulation of SMAD2 confirm-
ing that TAZ is essential for TGFb signaling. TAZ is overexpressed in
cancer cells and in the absence of TGF-b, TAZ showed no effects of
SMAD2 distribution in the cytoplasm and nucleus of the cells
[Varelas et al., 2008; Boggiano and Fehon, 2012]. In high-density
cell cultures, crumbs polarity complex is formed, which interacts
with and relays cell density information to TAZ/YAP by promoting
its phosphorylation, cytoplasmic retention, and suppression of
TGF-b signaling. Studies have shown that disruption of the crumbs
complex results in increased SMAD, TAZ, and YAP nuclear
accumulation, intensify sensitivity to the TGF-b ligand, and
promotes TGF-b-mediated epithelial-to-mesenchymal transition
[Varelas et al., 2010].
RAS PATHWAY
RAS, also called small GTPase, is a family of related proteins that are
expressed in cells and implicated in transmitting signals within cells.
Once RAS is “switched on” via incoming signals, it then switches on
other proteins, which eventually turn on genes associated with cell
growth, differentiation, and survival. Consequently, mutations in
RAS genes result in production of activated RAS proteins, which
cause unintentional and overactive signaling inside the cell, leading
to cancer development. TGF-b is a potent inhibitor of epithelial cell
proliferation, and the mechanism by which it inhibits is through
activation of the cyclin-dependent kinase inhibitors (CDKIs)
p15Ink4B and p21Cip1 and by suppression of c-myc and inhibitors
of differentiation (IDs). The tumor-suppressive functions of TGF-b
signaling are detected in epithelial tissues under physiological
conditions and during early stages of tumorigenesis. RAS signaling
is suggested to be involved in the conversion of anti- to pro-
oncogenic TGF-b signaling effects in late stages of cancer [Grusch
et al., 2010]. There is clear evidence that TGF-b and RAS play a
significant role in advancing benign mammary, prostate and lung
tumors to undifferentiated invasive tumors [Grusch et al., 2010]. In
the intestinal epithelium, the crosstalk between TGF-b and RAS is
revealed by overexpression of K-RAS and deletion of TGFbRII,
resulting in the generation of metastatic adenocarcinomas in
conjunction with stimulated epidermal growth factor (EGF) signal-
ing independent of Wnt/b-catenin. In breast and pancreatic cancer
cells, interaction of K-RAS and TGF-b signaling is delineated by
induction of Snail, a transcriptional repressor of RIN1, a RAB5
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guanine nucleotide exchange factor (GEF). RAB5 is known to
downregulate receptor tyrosine kinases and promote TGF-b
signaling by augmenting endocytosis of TGFbR complex, causing
an increased cell migration and invasion [Hu et al., 2008; Grusch
et al., 2010].
PI3K/AKT PATHWAY
Phosphatidylinositol 3-kinase, (PI3K)/AKT signaling pathway is
activated in cancers and contributes to proliferation, survival,
motility, and angiogenesis that are important for the growth and/or
maintenance of tumors. The PI3K/AKT activity is known to abate
TGF-b-induced apoptosis and/or cell cycle arrest in cells by blocking
nuclear translocation of SMAD3. An alternative pathway by which
PI3K/ AKT obstruct SMAD3 is via inactivation of nuclear factors
essential for SMAD3 function.
TGF-b treatment of HER2-expressing breast cancer cells increases
AKT activity which is essential for cell migration. Crosstalk of TGF-b
and PI3K/AKT is revealed in oncogene-overexpressing mammary
epithelial cells as PI3K inhibitors have shown inhibition of TGF-b-
induced motility. Further studies confirmed the interaction by
showing blockade of TGF-b–induced epithelial to mesenchymal
transition using PI3K inhibitor LY294002 or with expression of dn-
AKT. Upon treatment of epithelial pancreatic carcinoma cells with
TGF-b1, the TGFbRII associates with the E-cadherin/catenin
complex and facilitates the disassembly of the E-cadherin adhesion
complex which decreases E-cadherin and increases phosphorylation
of b-catenin and affects cell-cell adhesion. Crosstalk between the
two pathways is further substantiated in mammary epithelial cell
lines where TGF-b1 induced EMT activates PI3-kinase and AKT,
which results in alteration of E-cadherin at adherens junctions and
changes in SMAD4 regulated gene expression [Guo andWang, 2009;
Papageorgis, 2015].
LONG NON-CODING RNAs
Apart from interaction of TGF-b with other signaling pathways,
emerging studies suggest interactions of Long non-coding RNAs
(lncRNAs) and TGF-b. The lncRNAs are transcribed RNA molecules
of more than 200 nucleotides that either do not encode proteins or
lack>100 amino acid open reading frame. They play a crucial role in
various biological processes. Increasing evidence suggests their
association with carcinogenesis. Crosstalks between TGF-b and a
number of lncRNAs such as Metastasis-associated lung adenocarci-
noma transcript 1 (MALAT1), Maternally expressed gene 3 (MEG3),
plasmacytoma variant translocation 1 (PVT1), Linc00974, urothelial
carcinoma antigen 1 (UCA1), and BRAF-activated non-coding RNA
(BANCR) are reported to regulate the TGF-b signaling in cancer.
Interaction of TGF-b and MALAT1 was shown in multiple myeloma
cells where knockdown of MALAT1 inhibited production of TGF-b
and subsequently suppressed cell growth. Furthermore, MALAT1 has
been shown to regulate the bioavailability of TGF-b in mesenchymal
stem cells by promoting the activation of latent TGF-b binding
protein 3 (LTBP3) promoter via recruitment of Sp1 to the LTBP3
gene. Interaction between lncRNAs and TGF-b is further supported
by investigations revealing inhibition of TGF-b induced EMT in
bladder cancer cells by silencing MALAT1 [Wang et al., 2016]. In
addition, many TGF-b pathway genes such as TGF-b2, TGF-b2RI,
and SMAD2 have binding sites for MEG3 RNA. He et al. [2014]
found downregulation of MEG3 in TGF-b treated human hepatic
stellate cell line, LX-2. Ectopic expression of MEG3 in LX-2 cells
inhibited TGF-b-induced cell proliferation and stimulated apoptosis.
Although new knowledge of lncRNAs and TGF-b crosstalk is yet to
emerge, lncRNAs appear to be potential targets to adjust TGF-b
signaling pathway.
PROGESTINS
Progestins emerge to offer protection against gynecological cancers.
They are routinely used to treat endometrial and ovarian cancer
patients. The mechanisms by which progestins act as anti-cancer
agents is not known. Endometrial cancer cells produce and secrete
high levels of TGF-b, which is associated with tumor aggressiveness.
Progesterone significantly reduced TGF-b ligands, receptors and
SMAD2/3 expression in endometrial cancer cells. The mechanism by
which progesterone illustrates its inhibitory effects on TGF-b
signaling is by preventing translocation of activated SMAD2/3 to
the nucleus. This inhibitory effect was not seen when cells were
exposed to progesterone receptor antagonist Mifepristone. In
addition, progesterone inhibited TGF-b1 induced cell proliferation
and invasive potential of endometrial cancer cells while a TGF-bR1
blocker abolished inhibitory effects of progesterone. Furthermore, we
have demonstrated inhibition of snail, slug, vimentin, N-cadherin and
enhancement of E-cadherin in progesterone exposed cells [Bokhari
et al., 2014]. Another study has also reported EMT inhibition in
response to progesterone [van der Horst et al., 2012]. All these results
point to crosstalk between TGF-b signaling and progesterone.
NESTIN
Nestin is an intermediate filament protein and is a marker of stem
cells. Nestin by interacting with vimentin or desmin forms polymers
which provide structural support to cells and maintain cellular
membranes. There is limited literature on nestin and TGF-b
interaction. A study indicated a positive relationship between nestin
and TGFb signaling pathway in pancreatic cancer [Su et al., 2013].
We compared expression of nestin and TGF-b in immortalized
epithelial endometrial cells and in endometrial cancer cells and
showed higher expression of both in cancer cells. A direct
relationship between the two have been shown by shRNA mediated
knockdown or by ectopic expression of nestin in endometrial cancer
cells. Knockdown of nestin diminished TGF-b1, TGFbRs, and
phosphorylated SMAD2/3 but not SMAD4 and inhibited endometrial
cancer cell growth in vitro and in vivo. Furthermore, nestin
knockdown inhibited TGF-b1 induced EMT as revealed by down-
regultion of EMT markers and upregulation of E-cadherin. In
contrast, nestin overexpression showed an inverse expression
pattern of TGFb signaling components, EMT proteins expression
and enhanced invasive potential of cancer cells (our unpublished
data). These results strongly support interdependence of nestin and
TGF-b signaling on regulating tumor progression.
CONCLUSIONS AND FUTURE PERSPECTIVES
TGF-b has a major role in a variety of cancer types during
progression and metastasis. Increased levels of TGF-b in the
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tumor and its microenvironment promote tumorigenesis by
inducing EMT and facilitating tumor cell proliferation, thus
making it a druggable target. At present, diverse therapeutic
approaches are being tested in clinical trials and several preclinical
investigations are evaluating the efficacy of synthetic and natural
anticancer/antimetastatic molecules. Emphasis is placed on blockers
of TGF-b activation, neutralizing antibodies against TGF-b-receptor
interaction, inhibitors of TGF-b receptor kinase activity, ligand
traps, antisense oligonucleotides, peptide aptamer, and natural
products.
TGF-b signaling is altered in tumor cells, thus TGF-b inhibitors
may have restricted effects on these cells but may affect TGF-b
responsive cells in the tumor microenvironment. Studies have linked
TGF-b signaling with tumor microenvironment demonstrating the
promotion of angiogenesis andmetastasis. TGF-b inhibition therapy
may be tailored to normalize tumor microenvironment by inhibiting
stromal stimulation, which results from excess production of TGF-b
and other factors from tumors. Knowledge gained from tumor and
stromal cells may be instrumental in identifying new molecular
targets for developing novel TGF-b inhibitors. Nonetheless, there are
still many hurdles in developing and employing TGF-b inhibitors in
patients. Timing of treatment and selection of patients who would
benefit from TGF-b inhibition treatment are critical. TGF-b
inhibition may be a better preventive strategy for early stage
cancers, as tumors resulting from chronic inflammation have
elevated levels of TGF-b prior to tumor formation and form an
attractive microenvironment for cancer cells. TGF-b inhibitor
treatment can be beneficial as adjuvant therapy after complete
resection of tumor. TGF-b inhibitors target the tumor microenvi-
ronment and have minimal effect on cell proliferation. To
circumvent this issue, a combination of cytotoxic agents along
with TGF-b inhibitors would enhance antitumorogenic effects
compared to TGF-b inhibitors alone. Thus, targeting the TGF-b
signaling pathway alone may not be sufficient to abrogate tumor
growth. A synergistic response may be attained by concurrently
targeting other aberrant signaling pathways such as EGFR, PI3K/
AKT, NF-kB, JAK/STAT. Preclinical studies in pancreatic tumors
targeting the EGFR and TGF-b signaling pathways simultaneously
exhibited better efficacy than targeting either signaling pathway
alone. Clinical studies assessing the effects of the TGFbRI kinase
inhibitor LY-2157299 in combination with Sorafenib (a small
molecular inhibitor of multiple tyrosine protein kinases and Raf
kinases) in hepatocellular carcinoma support the notion that
combined treatment is more effective than a single treatment in
inhibiting tumor growth. While several antagonists are being
assessed in clinical trials, their long-term efficiency and potential
adverse side effects are not known. It is challenging to predict
whether complete blocking of TGF-b with inhibitors would be
sufficient to block the tumor promoting effects of TGF-b without
affecting its tumor suppressive functions. Thus, it is important to
develop novel strategies to target or manipulate the downstream
signaling components of the TGF-b pathway. To avoid the side
effects and drug resistance associated with long-term use of existing
TGF-b blockers, future studies should explore whether combinato-
rial or sequential treatments of anti-TGF-b drugs with irradiation or
chemotherapy will be beneficial. Furthermore, concomitantly
aiming multiple targets may prove to be an effective therapy as
TGF-b interacts with many signaling pathways. Profound under-
standing of TGF-b and its networking pathways that regulate its
outcome in tumors cells will assist in selecting drug combinations for
tumors.
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